Full Year 2023 Investor Presentation
20
Investor presentation
Full year 2023
Novo Nordisk Corporate Strategy
Diabetes
Strengthen leadership by
offering innovative medicines
and driving patient
outcomes
Rare Disease
Secure a leading position
by leveraging full portfolio
and expanding into
adjacent areas
Novo
Nordisk Way
Driving change
to defeat serious
chronic diseases
Sustainable business
Obesity
Strengthen leadership through
market development and by
offering innovative medicines
and driving patient outcomes
Cardiovascular &
Emerging Therapy
Areas¹
Establish position in
cardiovascular disease and
build a presence in emerging
therapy areas
1: Other Serious Chronic Diseases (OSCD) has been renamed to Cardiovascular & Emerging Therapy Areas (CETA) to reflect that cardiovascular disease has been the main strategic priority within OSCD
Novo NordiskⓇView entire presentation